GlassScriptPhysician profile
Mackenzie B Montag
NPI 1609439371
$2,267.00
in general payments reported to CMS, 2019-2025
17 companies · $590 in 2025
The $590 reported for 2025 was more than what 93% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $525 · 2023: $449 · 2024: $444 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436 · Education: $47.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.61 |
| Education | $47.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $355.36 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $353.59 | 2022-2025 | Dupixent |
| Abbvie INC. | $345.92 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.61 | 2021-2024 | Gattex, Eohilia |
| Qol Medical, LLC | $210.00 | 2021-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $200.44 | 2021-2022 | |
| Janssen Biotech, INC. | $197.66 | 2024-2025 | Tremfya, Stelara |
| Pharming Healthcare, INC. | $80.75 | 2022-2023 | Ruconest |
| Mirum Pharmaceuticals, INC. | $66.08 | 2022-2025 | Cholbam, Livmarli |
| Ipsen Biopharmaceuticals, INC | $52.54 | 2025 | Bylvay |
| Celltrion USA INC. | $32.70 | 2023 | Yuflyma |
| Aimmune Therapeutics, INC. | $32.51 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $30.48 | 2025 | Ultomiris |
| Acadia Pharmaceuticals INC | $29.62 | 2024 | Daybue |
| Organon LLC | $17.85 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.87 | 2024 | |
| Travere Therapeutics, INC. | $1.02 | 2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Montag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.